Lucid Diagnostics Inc. LUCD R2K
Healthcare · Medical Devices · United States
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
READ MORE ›$1.03
-25.90% 1Y
Market & Price
Market Cap
$196.48M
Current Price
$1.03
High / Low (52W)
$1.47 / $0.95
Beta
1.10
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$-0.04
Price to Book
-27.84
P/S
38.27
EV/EBITDA
-4.22
Dividend Yield
-
Profitability & Returns
ROCE
-
ROE
-
ROA
-92.09%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.17
EPS (TTM)
$-0.34
Balance Sheet & Liquidity
Debt/Equity
6.70
Quick Ratio
1.02
Current Ratio
1.07
Debt
$26.80M
Total Assets
$40.45M
Current Assets
$37.47M
Working Capital
$8.89M
Ownership
Promoter Holding
26.53%
Chg in Prom Hold
-
FII / Inst Holding
19.37%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$204.06M
Total Revenue (TTM)
$5.13M
EBITDA
$-48.39M
Free Cash Flow
$-25.52M
Operating Cash Flow
$-46.12M
Shares Outstanding
190.76M
Gross Margin
-31.36%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
131.97%
Profit 5Y
-1.09%
Revenue (YoY)
51.70%
Earnings (YoY)
-
PROS
- Compounding revenue at 132.0% over 5 years.
CONS
- Earnings shrank at -1.1% CAGR over 5 years.
- Trading 29.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LUCD Lucid Diagnostics Inc. R2K | 1.03 | - | $196.48M | - | - | - | 131.97% | -1.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 189.00K | - | 76.00K | 446.00K | 159.00K | 783.00K | 1.00M | 976.00K | - | - | 828.00K | 1.16M | 1.21M | 1.50M | 1.26M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.55M | 1.56M | 1.70M | 1.86M | 1.62M |
| Gross Profit | - | - | - | 200.00K | -180.00K | - | 76.00K | - | - | - | - | - | - | - | -723.00K | -400.00K | -486.00K | -356.00K | -369.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.76M | 10.98M | 11.27M | 13.65M | 11.74M |
| Operating Income | -2.02M | -3.65M | -6.02M | -6.51M | -12.27M | -14.63M | -14.38M | -14.32M | -11.58M | -11.13M | -10.79M | -11.19M | - | - | -12.49M | -11.38M | -11.76M | -14.01M | -12.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.68M | -4.21M | -10.18M | -16.05M | -13.68M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.00K | 6.00K | 2.00K | 6.00K | 6.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.91M | -4.44M | -10.40M | -16.27M | -13.91M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -2.02M | -3.65M | -6.16M | -6.96M | -12.27M | -14.62M | -14.35M | -16.25M | -11.38M | -14.21M | -10.61M | -11.01M | - | - | -26.91M | -4.44M | -10.40M | -16.27M | -13.91M |
| Diluted EPS | - | - | - | - | - | -0.41 | -0.39 | -0.40 | -0.27 | -0.34 | -0.40 | -0.23 | - | - | -0.52 | -0.08 | -0.10 | -0.10 | -0.17 |
| R&D Expense | 1.22M | 1.75M | 1.87M | 2.19M | 2.88M | 3.44M | 2.70M | 1.89M | 1.83M | 1.61M | 1.50M | 1.37M | 1.67M | - | 1.43M | 1.25M | 1.27M | - | 1.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 500.00K | 377.00K | 2.43M | 4.35M | 4.71M |
| Cost of Revenue | - | - | 3.61M | 5.98M | 7.10M | 6.67M |
| Gross Profit | - | 500.00K | -3.24M | -3.55M | -2.75M | -1.96M |
| Operating Expenses | - | - | 53.01M | 44.93M | 43.30M | 47.68M |
| Operating Income | -8.28M | -27.42M | -56.25M | -48.48M | -46.05M | -49.64M |
| EBITDA | - | - | -54.23M | -49.75M | -44.34M | -57.12M |
| Interest Expense | - | - | 8.00K | 416.00K | 26.00K | 22.00K |
| Pretax Income | - | - | -56.17M | -52.67M | -45.53M | -58.01M |
| Tax Provision | - | - | 0 | 0 | 0 | 0 |
| Net Income | -8.28M | -28.08M | -56.17M | -52.67M | -45.53M | -58.01M |
| Diluted EPS | - | - | -1.55 | -1.26 | -1.05 | -0.43 |
| R&D Expense | 5.44M | 9.30M | 11.26M | 7.25M | 5.99M | 5.68M |
Compounded Sales Growth
| 5 Years: | 131.97% |
| 1 Year: | 51.70% |
Compounded Profit Growth
| 5 Years: | -1.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -25.90% |
| 6 Months: | -5.50% |
| 3 Months: | -28.47% |
| 1 Month: | +0.00% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.19M | - | 32.51M | 27.27M | 30.71M | 40.45M |
| Current Assets | - | - | - | 24.36M | 22.07M | 25.15M | 37.47M |
| Cash & Equivalents | - | - | - | 22.47M | 18.90M | 22.36M | 34.70M |
| Inventory | - | - | - | 111.00K | 278.00K | 341.00K | 353.00K |
| Receivables | - | - | - | 17.00K | 45.00K | 45.00K | 643.00K |
| Total Liabilities | - | 15.71M | - | 9.46M | 29.58M | 25.32M | 29.51M |
| Current Liabilities | - | - | - | 8.43M | 29.38M | 23.52M | 28.58M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 2.00M | 15.26M | 21.25M | 25.82M |
| Total Equity | -5.31M | -13.52M | - | 23.05M | -2.31M | 5.39M | 10.94M |
| Shares Outstanding | - | - | - | 40.52M | 42.33M | 63.07M | 131.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.63M | - | -29.68M | -32.82M | -44.14M | -46.48M |
| Investing Cash Flow | - | - | -4.11M | -221.00K | -646.00K | -197.00K |
| Financing Cash Flow | 5.58M | - | 2.61M | 29.46M | 48.25M | 59.03M |
| Capital Expenditure | - | - | -908.00K | -221.00K | -646.00K | -197.00K |
| Free Cash Flow | - | - | -30.59M | -33.04M | -44.79M | -46.68M |
| Net Change in Cash | - | - | -31.18M | -3.58M | 3.46M | 12.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | 100.0% | -858.6% | -146.3% | -63.3% | -41.7% |
| Operating Margin % | - | -5,483.8% | -14,920.7% | -1,996.8% | -1,059.6% | -1,054.8% |
| Net Margin % | - | -5,615.6% | -14,899.5% | -2,169.1% | -1,047.6% | -1,232.7% |
| ROE % | 61.3% | - | -243.7% | 2,278.9% | -844.5% | -530.4% |
| ROCE % | - | - | -233.6% | 2,295.5% | -640.4% | -418.4% |
Shareholding Pattern
Insiders
26.53%
Institutions
19.37%
Public Float
26.36%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 2.28% | 4.64M | $4.78M |
| 2 | Vanguard Capital Management LLC | 2.05% | 4.15M | $4.28M |
| 3 | Masters Capital Management, LLC | 1.97% | 4.00M | $4.12M |
| 4 | Aberdeen Group plc | 1.79% | 3.64M | $3.75M |
| 5 | Two Seas Capital Lp | 1.48% | 3.00M | $3.09M |
| 6 | Geode Capital Management, LLC | 1.11% | 2.25M | $2.31M |
| 7 | Russell Investments Group, Ltd. | 0.78% | 1.58M | $1.63M |
| 8 | State Street Corporation | 0.77% | 1.55M | $1.60M |
| 9 | Wells Fargo & Company | 0.63% | 1.27M | $1.31M |
| 10 | Perkins Capital Management, Inc. | 0.55% | 1.13M | $1.16M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LUCD
No recent headlines available.